Marlena Broncel
Overview
Explore the profile of Marlena Broncel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
1014
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dyrbus K, Banach M, Gil R, Gasior M, Broncel M, Gellert R, et al.
Kardiol Pol
. 2025 Mar;
PMID: 40066957
Atherosclerosis is a systemic disease and involves not only the coronary vessels but also occurs in other vascular beds (e.g., cervical, cerebral, and peripheral vessels), increasing cardiovascular risk. One of...
2.
Satala J, Witkowska A, Pawlos A, Wozniak A, Broncel M, Wozniak E, et al.
Pol Arch Intern Med
. 2025 Mar;
PMID: 40035162
Introduction: Recently, interest has been growing in lipoprotein(a) (Lp(a)) as an independent risk factor for cardiovascular diseases. European Society of Cardiology (ESC) recommends a single measurement of Lp(a) concentration as...
3.
Wierzbowska-Drabik K, Witkowska A, Mozdzan M, Mozdzan M, Broncel M, Broncel M
Pol Arch Intern Med
. 2024 Aug;
134(12).
PMID: 39189391
No abstract available.
4.
Wozniak A, Satala J, Gorzelak-Pabis P, Pawlos A, Broncel M, Kazmierski P, et al.
J Cell Mol Med
. 2024 Jul;
28(14):e18459.
PMID: 39039803
Atherosclerotic plaque instability increases the risk of stroke. As such, determining the nature of an instability atherosclerotic plaque may speed up qualification for carotid endarterectomy (CEA), thus reducing the risk...
5.
Solnica B, Sygitowicz G, Sitkiewicz D, Jozwiak J, Kasperczyk S, Broncel M, et al.
Arch Med Sci
. 2024 May;
20(2):357-374.
PMID: 38757022
Lipid disorders are the most common (even 70%) and worst monitored cardiovascular risk factor (only 1/4 of patients in Poland and in CEE countries are on the low-density lipoprotein cholesterol...
6.
Warzywoda J, Pawlos A, Wozniak E, Broncel M, Gorzelak-Pabis P
Pol Arch Intern Med
. 2024 Mar;
134(3).
PMID: 38506101
No abstract available.
7.
Wozniak E, Broncel M, Wozniak A, Satala J, Pawlos A, Bukowska B, et al.
Sci Rep
. 2024 Jan;
14(1):2564.
PMID: 38297066
Heterozygous familial hypercholesterolemia (HeFH) is a common autosomal-dominant inherited disorder associated with atherosclerotic cardiovascular disease (ASCVD). HeFH subjects have a higher lipoprotein(a), i.e. Lp(a), concentration than the general population. Patients...
8.
Wozniak E, Swistek M, Broncel M, Bukowska B, Gorzelak-Pabis P
Biomed Pharmacother
. 2023 Dec;
170:116065.
PMID: 38154272
Background: Diabetes patients often suffer chronic vascular complications resulting from endothelial dysfunction, smooth muscle cell (SMC) proliferation, inflammation and disturbed oxidative balance. Empagliflozin is one of three approved sodium-glucose cotransporter...
9.
Zheng E, Madura P, Grandos J, Broncel M, Pawlos A, Wozniak E, et al.
Biomed Pharmacother
. 2023 Dec;
170:115966.
PMID: 38061135
Statins, also known as HMG-CoA reductase inhibitors, are one of the most potently prescribed and thoroughly researched medications, predominantly utilized for managing cardiovascular diseases by modulating serum cholesterol levels. Despite...
10.
Satala J, Wozniak A, Fabis M, Gorzelak-Pabis P, Pawlos A, Fabis J, et al.
Epidemiol Infect
. 2023 Aug;
151:e140.
PMID: 37554121
SARS-CoV-2 has become one of the most important and challenging medical research topics in recent years. The presence of endothelial dysfunction, immune thrombosis, and oxidative stress contributes to complications and...